EPA action: approved on February 18, 1988

Revision to use designation for one stream segment.

Adopted or amended by the State: September 10, 1983

EPA action: approved on February 18, 1988

Revision to use designations for six stream segments.

Adopted or amended by the State: May 4, 1985

EPA action: approved on February 18, 1988

Temporary (October 1, 1987 to April 30, 1988) suspension of the fecal coliform bacterial standard in tidal portions of the Delaware River.

Adopted or amended by the State: July 21, 1987

EPA action: approved on November 13, 1987

Revisons to use designations for five stream segments.

Adopted or amended by the State: September 5, 1987

EPA action: approved on February 18, 1988

Puerto Rico—EPA Region 2

Water quality standards for Puerto Rico are contained in: "Puerto Rico Water Quality Standards Regulation" as amended.

Amendments to Article 1, Definitions, and Article 5, Mixing zones, by Puerto Rico Environmental Quality Board resolution R-87-36-3.

Adopted or amended by the State: November 5, 1987

EPA action: approved on February 3, 1988

Texas—EPA Region 6

Water quality standards for the State of Texas are contained in: "Texas Administrative Code, Title 31 Natural Resources and Conservation, Chapter 307—Supplemental Surface Water Quality Standards and Chapter 333—Water Quality Management, sections 11-21, Surface Water Quality Standards" as amended.

Triennial review revisions include addition of numeric criteria to protect aquatic life, and incorporation of implementation procedures for antidegradation, toxic pollutants and variances.

Adopted or amended by the State: April 7, 1988

EPA action: approved on June 29, 1988

Utah—EPA Region 8

State water quality standards for the surface waters of the State of Utah are contained in the document entitled: "Part II of the Utah Wastewater Disposal Regulations, Standards of Quality for Waters of the State."

Triennial review providing for miscellaneous changes, including adoption of criteria for toxic pollutants, revisions to criteria for total residual chlorine and dissolved oxygen, revision to the mixing zone policy, designation of use classifications and amendments to the antidegradation standard.

Adopted or amended by the State: April 21, 1988; July 13, 1988 submittal to EPA incomplete.

EPA action: suspended pending completion of the Utah submittal

Virginia—EPA Region 3

Water quality standards for the State of Virginia are adopted pursuant to section 62.1-14.15(3) of the Code of Virginia (1950), as amended.

Revisions to eight chemical criteria.

Adopted or amended by the State: December 11, 1986

EPA action: approved on November 30, 1987

Triennial review of water quality standards.

Adopted or amended by the State: September 29, 1987

EPA action: approved in part April 21, 1988.

[FR Doc. 89-10472 Filed 5-1-89; 8:45 am]

BILLING CODE 6560-50-M

FEDERAL HOME LOAN BANK BOARD

Metropolitan Federal Savings and Loan Association, Denville, NJ; Appointment of Conservator

Notice is hereby given that pursuant to the authority contained in section 406(c)(1)(B)(i)(I) of the National Housing Act, as amended, 12 U.S.C. 1729(c)(1)(B)(i)(I) (1982), the Federal Home Loan Bank Board has duly appointed the Federal Savings and Loan Insurance Corporation as sole conservator for Metropolitan Federal Savings and Loan Assocaition, Denville, New Jersey on April 27, 1989.

Dated: April 27, 1989.

John M. Buckley, Jr.,

Secretary.

[FR Doc. 89-10483 Filed 5-1-89; 8:45 am]

BILLING CODE 6720-01-M

Seabank Savings, FSB, Myrtle Beach, SC; Appointment of Conservator

Notice is hereby given that pursuant to the authority contained in section 5(d)(6)(A)(i), of the Home Owner's Loan Act of 1933, as amended, 12 U.S.C. 1464(d)(6)(A)(i), and 12 U.S.C. 1701c(c)(2)(1982), as amended, the Federal Home Loan Bank Board duly appointed the Federal Savings and Loan Insurance Corporation as sole conservator for SeaBank Savings, FSB, Myrtle Beach, South Carolina on April 27, 1989.

Dated: April 27, 1989.

John M. Buckley, Jr.,

Secretary.

[FR Doc. 89-10484 Filed 5-1-89; 8:45 am]

BILLING CODE 6720-01-M

Southwest Savings and Loan Association; Los Angeles, CA; Appointment of Conservator

Notice is hereby given that pursuant to the authority contained in section 406(c)(1)(B)(i)(I) of the National Housing Act, as amended, 12 U.S.C. 1729(c)(1)(B)(i)(I) (1982), the Federal Home Loan Bank Board has duly appointed the Federal Savings and Loan Insurance Corporation as sole conservator for Southwest Savings and Loan Association, Los Angeles, California on April 27, 1989.

Dated: April 27, 1989.

John M. Buckley, Jr.,

Secretary.

[FR Doc. 89-10485 Filed 5-1-89; 8:45 am]

BILLING CODE 6720-01-M

Westco Savings Bank, FSB; Wilmington, CA; Appointment of Conservator

Notice is hereby given that pursuant to the authority contained in section 5(d)(6)(A)(i), of the Home Owner's Loan Act of 1933, as amended, 12 U.S.C. 1464(d)(6)(A)(i), and 12 U.S.C. 1701c(c)(2)(1982), as amended, the Federal Home Loan Bank Board has duly appointed the Federal Savings and Loan Insurance Corporation as sole conservator for Westco Savings Bank, FSB, Wilmington, California, on April 27, 1989.

Dated: April 27, 1989.

John M. Buckley, Jr.,

Secretary.

[FR Doc. 89-10486 Filed 5-1-89; 8:45 am]

BILLING CODE 6720-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 89F-0111]

Rhone-Poulenc, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a food additive petition has been filed by Rhone-Poulenc, Inc., proposing that the food additive regulations be amended to provide for the safe use of alkyl (C_{14}–C_{30}) benzene as a component of adhesives for articles intended to contact food.

FOR FURTHER INFORMATION CONTACT: Marvin D. Mack, Center for Food Safety and Applied Nutrition (HFF–335), Food and Drug Administration, 200 C Street SW., Washington, DC 20204, 202–472–5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 9B4140) has been filed by Rhone-Poulenc, Inc., 1669 Corporate Rd. West, Lakewood, NJ 08071, proposing that § 175.105 *Adhesives* (21 CFR 175.105) be amended to provide for the safe use of alkyl (C_{14}–C_{30}) benzene as a component of adhesives for articles intended to contact food.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: April 24, 1989.

Fred R. Shank,

Acting Director, Center for Food Safety, and Applied Nutrition.

[FR Doc. 89–10461 Filed 5–1–89; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 89F-0107]

United Catalysts, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that United Catalysts, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of bentonite, modified with benzyl (hydrogenated tallow alkyl) dimethyl ammonium chloride, as a rheological modifier in resinous and polymeric coatings complying with 21 CFR 175.300, for use in contact with food.

FOR FURTHER INFORMATION CONTACT: Rudolph Harris, Center for Food Safety and Applied Nutrition (HFF–335), Food and Drug Administration, 200 C Street SW., Washington, DC 20204, 202–472–5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 8B4112) has been filed by United Catalysts, Inc., P.O. Box 32370, Louisville, KY 40232, proposing that § 175.300 *Resinous and polymeric coatings* (21 CFR 175.300) be amended to provide for the safe use of bentonite, modified with benzyl (hydrogenated tallow alkyl) dimethyl ammonium chloride, as a rheological modifier in resinous and polymeric coatings for use in contact with food.

The potential environment impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: April 24, 1989.

Fred R. Shank,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 89–10462 Filed 5–1–89; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 89N-0146]

Drug Export; M.V.C. 9+4 (Pedriatric)

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that LyphoMed, Inc., has filed an application requesting approval for the export of the human drug M.V.C. 9+4 (Pedriatric) to Canada.

ADDRESS: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, Room 4–62, 5600 Fishers Lane, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Rudolf Apodaca, Division of Drug Labeling Compliance (HFD–310), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–295–8063.

SUPPLEMENTARY INFORMATION: The Drug Export Amendments Act of 1986 (Pub. L. 99–660) (section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382)) provides that FDA may approve applications for the export of drugs that are not currently approved in the United States. The approval process is governed by section 802(b) of the act. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that LyphoMed, Inc., 2045 North Cornell Ave., Melrose Park, IL 60160, has filed an application requesting approval for the export of the drug M.V.C. 9+4 (Pedriatric) to Canada. This product is used to intravenously treat multiple vitamin deficiencies, extensive burns, fractures, severe infectious diseases, and comatose states, which may provoke a stress situation with profound alterations in the body's metabolic demands and consequent tissue depletion of nutrients. The application was received and filed in the Center for Drug Evaluation and Research on April 17, 1989, which shall be considered the filing date for the purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by May 12, 1989,

and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802, Pub. L. 99-660 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Drug Evaluation and Research (21 CFR 5.44).

Dated: April 21, 1989.

Daniel L. Michels,

Director, Office of Compliance, Center for Drug Evaluation and Research.

[FR Doc. 89-10463 Filed 5-1-89; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 89N-0145]

Drug Export; Acetylcholine Chloride for Ophthalmic Solution, USP 20 Mg

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Steris Laboratories, Inc., has filed an application requesting approval for the export of the human drug Acetylcholine Chloride for Ophthalmic Solution, USP 20 mg to Canada.

ADDRESS: Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Rudolf Apodaca, Division of Drug Labeling Compliance (HFD-310), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-295-8063.

SUPPLEMENTARY INFORMATION: The Drug Export Amendments Act of 1986 (Pub. L. 99-660) (section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382)) provides that FDA may approve applications for the export of drugs that are not currently approved in the United States. The approval process is governed by section 802(b) of the act. Section 802(b)[(3)[B] of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Steris Laboratories, Inc., 620 North 51st Ave., Phoenix, AR 85043-4705, has filed an application requesting approval for the export of the drug Acetylcholine Chloride for Ophthalmic Solution, USP 20 mg, to Canada. This product is to be used to obtain complete miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid, complete miosis may be required. The application was received and filed in the Center for Drug Evaluation and Research on April 11, 1989, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by May 12, 1989, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802, Pub. L. 99-660 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Drug Evaluation and Research (21 CFR 5.44).

Dated: April 21, 1989.

Daniel L. Michels,

Director, Office of Compliance, Center for Drug Evaluation and Research.

[FR Doc. 89-10464 Filed 5-1-89; 8:45 am]

BILLING CODE 4160-01-M

Public Health Service

Health Resources and Services Administration; Health Education Assistance Loan Program; Maximum Interest Rates for Quarter Ending June 30, 1989

Section 727 of the Public Health Service Act (42 U.S.C. 294) authorizes the Secretary of Health and Human Services to establish a Federal program of student loan insurance for graduate students in health professions schools.

A. Section 60.13(a)(4) of the program's implementing regulations (42 CFR Part 60, previously 45 CFR Part 126) provides that the Secretary will announce the interest rate in effect on a quarterly basis.

The Secretary announces that for the period ending June 30, 1989, three interest rates are in effect for loans executed through the Health Education Assistance Loan (HEAL) program.

1. For loans made before January 27, 1981, the variable interest rate is 12⅜ percent. Using the regulatory formula (45 CFR 126.13(a) (2) and (3)) in effect prior to January 27, 1981, the Secretary would normally compute the variable rate for this quarter by finding the sum of the fixed annual rate (7 percent) and a variable component calculated by subtracting 3.50 percent from the average bond equivalent rate of 91-day U.S. Treasury bills for the preceding calendar quarter (8.87 percent), and rounding the result (12.37 percent) upward to the nearest ⅛ percent (12⅜ percent). However, the regulatory formula also provides that the annual rate of the variable interst rate for a 3-month period shall be reduced to the highest one-eighth of 1 percent which would result in an average annual rate not in excess of 12 percent for the 12-month period concluded by those 3 months. Because the average rate of the 4 quarters ending June 30, 1989, is not in excess of 12 percent, there is no necessity for reducing the interest rate. For the previous 3 quarters the variable interest at the annual rate was as follows: 10 percent for the quarter ending September 30, 1988; 10¾ percent for the quarter ending December 31, 1988; and 11½ percent for the quarter ending March 31, 1939.

2. For variable rate loans executed during the period of January 27, 1981 through October 21, 1985, the interest rate is 12⅜ percent. Using the regulatory formula (42 CFR 60.13(a)(3)) in effect for that time period, the Secretary computes the maximum interest rate at the beginning of each calendar quarter by determining the average bond equivalent rate for the 91-day U.S. Treasury bills during the preceding quarter (8.87 percent); adding 3.50 percent (12.37 percent); and rounding that figure to the next higher one-eighth of 1 percent (12⅜ percent).

3. For fixed rate loans executed during the period of April 1, 1989 through June 30, 1989, and for variable rate loans executed on or after October 22, 1985,